N1-Methylpseudouridine: Increase mRNA vaccine effectiveness
|
|
|
|
Replacement of Uridine with N1-Methylpseudouridine has been utilized in the COVID-19 mRNA vaccines developed by both Pfizer-BioNTech and Moderna.
Research suggests that incorporation of N1-Methylpseudouridine increases mRNA vaccine effectiveness through enhanced protein expression combined with low immunogenicity. Read more…
|
|
|
|
Responsible for content / Imprint:
Jena Bioscience GmbH
Loebstedter Str. 71 | 07749 Jena | Germany
Phone: +49 – 3641 – 6285 000 | Fax: +49 – 3641 – 6285 100 | E-Mail: info@jenabioscience.com
Register Court: Amtsgericht Jena, HRB 207171 | VAT No.: DE 195825742
Managing Directors: Thomas Billert | Dr. Mathias Grün
|
|
|
|
|
|
